Translational Genomics Research Institute
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.tgen.org
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
- Conditions
- Pancreatic CancerPancreas AdenocarcinomaAdvanced Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Translational Genomics Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03331562
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
Studies in Patients With Tuberous Sclerosis Complex
- Conditions
- Tuberous Sclerosis Complex
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Translational Genomics Research Institute
- Target Recruit Count
- 32
- Registration Number
- NCT03276195
- Locations
- 🇺🇸
Translational Genomics Research Institute (TGen), Phoenix, Arizona, United States
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Translational Genomics Research Institute
- Registration Number
- NCT00954876
- Locations
- 🇺🇸
Evergreen Hematology & Oncology, Spokane, Washington, United States
News
ARPIs Show Similar Efficacy in mHSPC Regardless of Disease Volume; Drug Selection Should Focus on Patient-Specific Factors
A systematic review of phase 3 trials reveals that all androgen receptor pathway inhibitors (ARPIs) demonstrate comparable efficacy outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients regardless of disease volume or metastasis timing.